Biogen Seeking FDA Approval For Alzheimer’s Drug
Biogen and Eisai have announced completion of the application to seek approval from the FDA for aducanumab, which is a drug that some testing has shown promise in early stage Alzheimer’s at slowing the disease. This submission is the first “filing for FDA approval of a treatment that addresses the clinical decline associated with the …